Table 4. Change from baseline in quality-of-life scores following immediate versus delayed injections of polyalkylimide gel injections in patients with human immunodeficiency virus–associated facial lipoatrophy [23]
|
|
Week 12 |
Week 48 |
||
|
|
Immediate Group (n=15) |
Delayed Group (n=15) |
Immediate Group (n=15) |
Delayed Group (n=15) |
|
Medical Outcomes Study HIV Health Survey |
|
|
|
|
|
Quality of life |
0 (0, 25) |
0 (0, 0)* |
75 (75, 75) |
75 (50, 75) |
|
Physical health |
80 (5, 102) |
11 (–43, 30) |
505 (372, 535) |
405 (320, 475) |
|
Mental health |
72 (22, 117) |
3 (–39, 23)* |
549 (477, 594) |
495 (389, 553) |
|
Hospital Anxiety and Depression Scale |
|
|
|
|
|
Depression |
–3 (–5, –1) |
–1 (–2, 0) |
8 (5, 11) |
7 (6, 10) |
|
Anxiety |
–3 (–5, –2) |
–1 (–2, 3)* |
8 (6, 13) |
9 (8, 12) |
|
Slightly modified Dermatology Quality of Life Survey |
–7 (–10, –1) |
1 (–1, 2)* |
0 (0, 3) |
1 (0, 3) |
Scores are median (interquartile range).
*P<0.05 between groups at week 12.
Adapted with permission from Loutfy MR et al, Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients, AIDS. 2007; 21:1147-1155 [23].